GHRH and GH signaling: a research overview
A neutral overview of the somatotropic axis and how GHRH analogues and secretagogues are studied in growth-signaling research. Educational only.
A neutral overview of growth-hormone-releasing-hormone (GHRH) and growth-hormone (GH) signaling as described in the research literature. This page is educational and describes mechanisms only.
The somatotropic axis
The somatotropic axis describes the hypothalamic–pituitary control of growth hormone. GHRH from the hypothalamus stimulates GH release from the pituitary; somatostatin opposes it; GH in turn drives downstream signaling including IGF/MGF growth-factor pathways. It is a classic feedback system studied extensively in endocrine research.
GHRH analogues and secretagogues
Two classes of reference peptide are studied here. GHRH analogues (such as CJC-1295 and sermorelin) mimic the releasing hormone, while GH secretagogues (such as ipamorelin and GHRP-6) act through the ghrelin/secretagogue receptor. See the encyclopedia entries for CJC-1295 and ipamorelin for structural context.
Research directions
Current literature explores receptor pharmacology, pulsatility of release, and the comparative signaling of analogue versus secretagogue classes. These are areas of basic and pre-clinical research; nothing here describes clinical use.
Research use only. All products and content are intended strictly for in-vitro laboratory research and analytical use. Not for human or veterinary use, not for consumption, and not for any diagnostic or therapeutic purpose.